New data suggests J&J vaccine works against delta variant and recipients don’t need a booster

In the trial, called Sisonke, researchers evaluated a dose of the Johnson & Johnson vaccine in nearly 500,000 healthcare workers, who are at high risk for COVID-19. The vaccine is up to 95% effective against death from the delta variant, and up to 71% against hospitalization, the researchers reported. (The vaccine performed slightly worse against the beta variant, which is believed to be more able to bypass the immune response than the delta variant.)